Prof. Dr. med. Christian Hagemeier

University Education

• 1980-1982 Medicine, University of Münster
• 1983-1984 M.D., Department of Biochemistry, Universität Münster
• 1984-1985 University of Cambridge and Oxford, UK
• 1986 University of Newcastle, Australia and Universität Münster, state examination

Professional Experience (selection)

• 1989-1992 Ph.D., University of Cambridge & Medical Research Council (MRC), Molecular Medicine Unit, UK
• 1992-1994 Postdoctoral research fellow, University of Cambridge, Cancer Research, UK
• 1995-2002 Head of DFG Clinical Research Group, Children’s Hospital, Charité
• To date      Head of the Laboratory of Pediatric Molecular Biology and Co-Head, Laboratory of Functional Genomics, Charité 

Research Fields

• i)    Molecular Oncology
• ii)   Epigenetics
• iii)  Cell cycle control 

Most important Awards, Grants or Scientific Achievements

• Head of DFG Clinical Research Group, Speaker of NGFN consortium Functional Genomics of Acute Leukemias

Selected References

• Bogdanow, B., Schmidt, M., Weisbach, H., Gruska, I., Vetter, B., Imami, K., Ostermann, E., Brune, W., Selbach, M., Hagemeier, C., & Wiebusch, L. (2020). Cross-regulation of viral kinases with cyclin A secures shutoff of host DNA synthesis. Nature communications, 11(1), 4845.
• Schiesser, S., Hackner, B., Pfaffeneder, T., Müller, M., Hagemeier, C., Truss, M., & Carell, T. (2012). Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angewandte Chemie (International ed. in English), 51(26), 6516–6520.
• Pfaffeneder, T., Hackner, B., Truss, M., Münzel, M., Müller, M., Deiml, C. A., Hagemeier, C., & Carell, T. (2011). The discovery of 5-formylcytosine in embryonic stem cell DNA. Angewandte Chemie (International ed. in English), 50(31), 7008–7012.
• Rhein, P., Mitlohner, R., Basso, G., Gaipa, G., Dworzak, M. N., Kirschner-Schwabe, R., Hagemeier, C., Stanulla, M., Schrappe, M., Ludwig, W. D., Karawajew, L., & Ratei, R. (2010). CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood, 115(18), 3763–3771.
• Pohlers, M., Truss, M., Frede, U., Scholz, A., Strehle, M., Kuban, R. J., Hoffmann, B., Morkel, M., Birchmeier, C., & Hagemeier, C. (2005). A role for E2F6 in the restriction of male-germ-cell-specific gene expression. Current biology : CB, 15(11), 1051–1057.
• Hof, J., Krentz, S., van Schewick, C., Körner, G., Shalapour, S., Rhein, P., Karawajew, L., Ludwig, W. D., Seeger, K., Henze, G., von Stackelberg, A., Hagemeier, C., Eckert, C., & Kirschner-Schwabe, R. (2011). Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(23), 3185–3193.
• Młynarczuk-Biały I, Roeckmann H, Kuckelkorn U, Schmidt B, Umbreen S, Gołab J, Ludwig A, Montag C, Wiebusch L, Hagemeier C, Schadendorf D, Kloetzel PM, Seifert U. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res. 2006 Aug 1;66(15):7598-605.
• Hof, J., Krentz, S., van Schewick, C., Körner, G., Shalapour, S., Rhein, P., Karawajew, L., Ludwig, W. D., Seeger, K., Henze, G., von Stackelberg, A., Hagemeier, C., Eckert, C., & Kirschner-Schwabe, R. (2011). Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(23), 3185–3193.
• Wiebusch, L., & Hagemeier, C. (2010). p53- and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress. Oncogene, 29(24), 3477–3489.
• Morkel, M., Wenkel, J., Bannister, A. J., Kouzarides, T., & Hagemeier, C. (1997). An E2F-like repressor of transcription. Nature, 390(6660), 567–568.